Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How I treat posttransplant lymphoproliferative disorders
Daan Dierickx, Thomas Tousseyn, Olivier Gheysens
Blood (2015) Vol. 126, Iss. 20, pp. 2274-2283
Open Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

Post-Transplantation Lymphoproliferative Disorders in Adults
Daan Dierickx, Thomas M. Habermann
New England Journal of Medicine (2018) Vol. 378, Iss. 6, pp. 549-562
Closed Access | Times Cited: 379
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczyński, Walter J. F. M. van der Velden, Christopher P. Fox, et al.
Haematologica (2016) Vol. 101, Iss. 7, pp. 803-811
Open Access | Times Cited: 335
Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Upton Allen, Jutta K. Preiksaitis
Clinical Transplantation (2019) Vol. 33, Iss. 9
Closed Access | Times Cited: 291
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Ralf Ulrich Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 5, pp. 536-543
Open Access | Times Cited: 205
Diagnosis of Hodgkin lymphoma in the modern era
Hao‐Wei Wang, Jayalakshmi Balakrishna, Stefania Pittaluga, et al.
British Journal of Haematology (2018) Vol. 184, Iss. 1, pp. 45-59
Open Access | Times Cited: 160
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
Jennifer L. Crombie, Ann S. LaCasce
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 87
Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches
Fedaey Abbas, Mohsen El Kossi, Ihab Sakr Shaheen, et al.
World Journal of Transplantation (2020) Vol. 10, Iss. 2, pp. 29-46
Open Access | Times Cited: 74
Post‐transplant lymphoproliferative disorder: Update on treatment and novel therapies
Suheil Albert Atallah‐Yunes, Omar Salman, Michael J. Robertson
British Journal of Haematology (2023) Vol. 201, Iss. 3, pp. 383-395
Open Access | Times Cited: 32
Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders
Julie Morscio, Thomas Tousseyn
World Journal of Transplantation (2016) Vol. 6, Iss. 3, pp. 505-505
Open Access | Times Cited: 67
Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation
Ayumi Fujimoto, Nobuhiro Hiramoto, Satoshi Yamasaki, et al.
Biology of Blood and Marrow Transplantation (2019) Vol. 25, Iss. 7, pp. 1441-1449
Open Access | Times Cited: 59
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Agnes Bonifacius, Britta Lamottke, Sabine Tischer‐Zimmermann, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 12
Open Access | Times Cited: 23
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults
Jeremy D. Rubinstein, Keri Toner, Thomas G. Gross, et al.
Best Practice & Research Clinical Haematology (2023) Vol. 36, Iss. 1, pp. 101446-101446
Open Access | Times Cited: 18
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation
Samuel Romero, Juan Montoro, Marta Guinot, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2018) Vol. 60, Iss. 1, pp. 142-150
Closed Access | Times Cited: 47
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy
Tanner C. Dalton, Ekaterina Doubrovina, Dmitry Pankov, et al.
Blood (2020) Vol. 135, Iss. 21, pp. 1870-1881
Open Access | Times Cited: 47
Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study
Jun Yang, Jieling Jiang, Yu Cai, et al.
Bone Marrow Transplantation (2018) Vol. 54, Iss. 7, pp. 1049-1057
Open Access | Times Cited: 45
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes
Ayumi Fujimoto, Ritsuro Suzuki
Cancers (2020) Vol. 12, Iss. 2, pp. 328-328
Open Access | Times Cited: 35
Biological Difference Between Epstein–Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact
Valeria Ferla, Francesca Gaia Rossi, Maria Goldaniga, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 34
Epstein‐Barr virus related post‐transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation
Julian Lindsay, Michelle K. Yong, Matthew Greenwood, et al.
Reviews in Medical Virology (2020) Vol. 30, Iss. 4
Open Access | Times Cited: 33
Mechanistic Understanding of EBV+ Lymphoproliferative Disease Development After Transplantation
Philippe L. Furlano, Georg A. Böhmig, Elisabeth Puchhammer‐Stöckl, et al.
Transplantation (2024) Vol. 108, Iss. 9, pp. 1867-1881
Closed Access | Times Cited: 4
Anti-CD20 Blocker Rituximab in Kidney Transplantation
Puneet Sood, Sundaram Hariharan
Transplantation (2017) Vol. 102, Iss. 1, pp. 44-58
Closed Access | Times Cited: 36
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
Efrat Luttwak, David Hagin, Chava Perry, et al.
Bone Marrow Transplantation (2020) Vol. 56, Iss. 5, pp. 1031-1037
Closed Access | Times Cited: 29
PD-1 Blockade Aggravates Epstein–Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations
Valery Volk, Sebastian J. Theobald, Simon Danisch, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 26
Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder
Mariam Markouli, Fauzia Ullah, Najiullah Omar, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5949-5949
Open Access | Times Cited: 17
Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation
Agata Marjańska, Jan Styczyński
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 6, pp. 539-552
Closed Access | Times Cited: 10
Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis
Yannan Jia, Xinxin Xia, Jun Yang, et al.
Annals of Hematology (2025)
Open Access
Page 1 - Next Page

Scroll to top